CY1123906T1 - Αναστολεις απομεθυλασης ιστονης - Google Patents

Αναστολεις απομεθυλασης ιστονης

Info

Publication number
CY1123906T1
CY1123906T1 CY20211100169T CY211100169T CY1123906T1 CY 1123906 T1 CY1123906 T1 CY 1123906T1 CY 20211100169 T CY20211100169 T CY 20211100169T CY 211100169 T CY211100169 T CY 211100169T CY 1123906 T1 CY1123906 T1 CY 1123906T1
Authority
CY
Cyprus
Prior art keywords
cancer
compounds
compositions
useful
treatment
Prior art date
Application number
CY20211100169T
Other languages
English (en)
Inventor
Amogh Boloor
Young K. Chen
Michael Brennan Wallace
Original Assignee
Celgene Quanticel Research, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Research, Inc. filed Critical Celgene Quanticel Research, Inc.
Publication of CY1123906T1 publication Critical patent/CY1123906T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Η παρούσα εφεύρεση αφορά γενικά συνθέσεις και μεθόδους για τη θεραπεία καρκίνου και νεοπλασματικών νόσων. Παρέχονται στο παρόν υποκατεστημένες ενώσεις παραγώγων πυριδίνης και φαρμακευτικές συνθέσεις που περιλαμβάνουν τις εν λόγω ενώσεις. Οι εν λόγω ενώσεις και συνθέσεις είναι χρήσιμες για την αναστολή απομεθυλάσης ιστόνης. Περαιτέρω οι εν λόγω ενώσεις και συνθέσεις είναι χρήσιμες για τη θεραπεία του καρκίνου, όπως καρκίνου του προστάτη καρκίνου του μαστού, καρκίνου της ουροδόχου κύστης, καρκίνου του πνεύμονα και/ή μελανώματος και παρομοίων.
CY20211100169T 2014-06-25 2021-03-01 Αναστολεις απομεθυλασης ιστονης CY1123906T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462017201P 2014-06-25 2014-06-25
PCT/US2015/037812 WO2015200709A1 (en) 2014-06-25 2015-06-25 Histone demethylase inhibitors

Publications (1)

Publication Number Publication Date
CY1123906T1 true CY1123906T1 (el) 2022-05-27

Family

ID=54929774

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100169T CY1123906T1 (el) 2014-06-25 2021-03-01 Αναστολεις απομεθυλασης ιστονης

Country Status (29)

Country Link
US (7) US10385047B2 (el)
EP (3) EP3741749A1 (el)
JP (1) JP6521535B2 (el)
KR (1) KR102591897B1 (el)
CN (2) CN106660982B (el)
AR (1) AR100997A1 (el)
AU (1) AU2015279719B2 (el)
BR (1) BR112016030367A2 (el)
CA (1) CA2953437C (el)
CL (1) CL2016003301A1 (el)
CO (1) CO2017000359A2 (el)
CY (1) CY1123906T1 (el)
DK (1) DK3160952T3 (el)
EA (1) EA031200B1 (el)
EC (1) ECSP17004931A (el)
ES (1) ES2862648T3 (el)
HR (1) HRP20210299T1 (el)
HU (1) HUE053876T2 (el)
IL (1) IL249629A0 (el)
LT (1) LT3160952T (el)
MX (1) MX2016017407A (el)
NZ (1) NZ728120A (el)
PL (1) PL3160952T3 (el)
PT (1) PT3160952T (el)
SA (1) SA516380585B1 (el)
SG (1) SG11201610813TA (el)
SI (1) SI3160952T1 (el)
TW (2) TWI758004B (el)
WO (1) WO2015200709A1 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100818A1 (en) 2012-12-21 2014-06-26 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
EP3741749A1 (en) 2014-06-25 2020-11-25 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US10030017B2 (en) 2014-09-17 2018-07-24 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
EP3453710B1 (en) 2014-09-17 2022-09-21 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CN108698997A (zh) * 2015-12-28 2018-10-23 赛尔基因昆蒂赛尔研究公司 组蛋白脱甲基酶抑制剂
JP6970681B2 (ja) * 2016-03-15 2021-11-24 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2018183370A2 (en) 2017-03-30 2018-10-04 Albert-Ludwigs-University Freiburg Kdm4 inhibitors
CN109825551B (zh) * 2019-02-21 2022-08-02 深圳大学 一种评价组蛋白赖氨酸去甲基转移酶活性的方法
CN111679072B (zh) * 2020-06-15 2022-04-29 温州医科大学 Kdm6b蛋白在乳腺癌预后评估试剂盒、诊断试剂盒中的应用
AU2022254741A1 (en) * 2021-04-09 2023-11-16 Celgene Corporation Treatment of cancer with kdm4 inhibitors
CA3227684A1 (en) * 2021-08-18 2023-02-23 Jr. Richard M. Heid Process for preparing histone demethylase inhibitors
WO2023122221A1 (en) * 2021-12-23 2023-06-29 Tachyon Therapeutics, Inc. Pharmaceutical formulations comprising 3-({[(4r)-7-{methyl[4-(propan-2-yl)phenyl]amino}-3,4-dihydro-2h-l-benzopyran-4-yl]methyl}amino)pyridine-4-carboxylic acid
WO2023250480A1 (en) * 2022-06-23 2023-12-28 The Cleveland Clinic Foundation 3-βHSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
WO2024064734A1 (en) * 2022-09-21 2024-03-28 Celgene Corporation Crystalline forms of 3-({[(4r)-7-{methyl[4-(propan-2- yl)phenyl]amino}-3,4-dihydro-2h-l-benzopyran-4- yl]methyl}amino)pyridine-4-carboxylic acid l-lysine salt, a histone demethylase inhibitor
CN115974647A (zh) * 2022-12-05 2023-04-18 江苏宏邦化工科技有限公司 以四氢-4-甲基-2-苯基-2h-吡喃-4-醇为原料制备苯乐戊醇的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1578663B (zh) * 2001-09-14 2011-05-25 梅特希尔基因公司 组蛋白脱乙酰化酶抑制剂
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
DE102004039876A1 (de) 2004-06-23 2006-01-26 Lanxess Deutschland Gmbh Herstellung von fluorierten 1,3-Benzodioxanen
PE20071020A1 (es) 2006-03-07 2007-12-11 Smithkline Beecham Corp Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa
US8598168B2 (en) * 2006-04-07 2013-12-03 Methylgene Inc. Inhibitors of histone deacetylase
US7898712B2 (en) 2008-06-27 2011-03-01 Lockheed Martin Corporation Risley integrated steering module
GB201112607D0 (en) * 2011-07-22 2011-09-07 Glaxo Group Ltd Novel compounds
WO2012149540A1 (en) * 2011-04-28 2012-11-01 The Broad Institute Inc Inhibitors of histone deacetylase
WO2013143597A1 (en) * 2012-03-29 2013-10-03 Glaxo Group Limited Demethylase enzymes inhibitors
US20140162266A1 (en) 2012-12-05 2014-06-12 Bio-Rad Laboratories, Inc. Methods for polymerase chain reaction copy number variation assays
ES2834959T3 (es) * 2012-12-06 2021-06-21 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa
JP6256772B2 (ja) * 2012-12-19 2018-01-10 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
WO2014100818A1 (en) * 2012-12-21 2014-06-26 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
EP3741749A1 (en) 2014-06-25 2020-11-25 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2018183370A2 (en) * 2017-03-30 2018-10-04 Albert-Ludwigs-University Freiburg Kdm4 inhibitors

Also Published As

Publication number Publication date
CN111909083B (zh) 2023-08-15
US20180251458A1 (en) 2018-09-06
US20150376169A1 (en) 2015-12-31
AU2015279719A1 (en) 2017-02-02
SG11201610813TA (en) 2017-01-27
EP3160952B1 (en) 2020-12-02
HUE053876T2 (hu) 2021-07-28
US9994561B2 (en) 2018-06-12
US20180044334A1 (en) 2018-02-15
US9586902B2 (en) 2017-03-07
SI3160952T1 (sl) 2021-07-30
KR20170018079A (ko) 2017-02-15
US9242968B2 (en) 2016-01-26
AU2015279719B2 (en) 2019-03-21
CL2016003301A1 (es) 2021-03-05
EP3160952A1 (en) 2017-05-03
HRP20210299T1 (hr) 2021-04-16
US9447046B2 (en) 2016-09-20
ECSP17004931A (es) 2017-03-31
US20170114055A1 (en) 2017-04-27
CN106660982A (zh) 2017-05-10
NZ728120A (en) 2023-06-30
KR102591897B1 (ko) 2023-10-19
PL3160952T3 (pl) 2021-07-19
EP3738960A1 (en) 2020-11-18
DK3160952T3 (da) 2021-03-08
TW202124369A (zh) 2021-07-01
US20160332970A1 (en) 2016-11-17
WO2015200709A1 (en) 2015-12-30
AR100997A1 (es) 2016-11-16
JP2017523152A (ja) 2017-08-17
TWI758004B (zh) 2022-03-11
EP3741749A1 (en) 2020-11-25
CO2017000359A2 (es) 2017-04-10
JP6521535B2 (ja) 2019-05-29
CA2953437C (en) 2022-08-30
ES2862648T3 (es) 2021-10-07
US9815828B2 (en) 2017-11-14
BR112016030367A2 (pt) 2018-07-17
TW201613882A (en) 2016-04-16
US20170158685A1 (en) 2017-06-08
EP3160952A4 (en) 2018-02-21
CN111909083A (zh) 2020-11-10
CA2953437A1 (en) 2015-12-30
US20160107995A1 (en) 2016-04-21
US10106534B2 (en) 2018-10-23
IL249629A0 (en) 2017-02-28
PT3160952T (pt) 2021-03-08
TWI715533B (zh) 2021-01-11
SA516380585B1 (ar) 2020-12-06
US10385047B2 (en) 2019-08-20
EA201692483A1 (ru) 2017-05-31
EA031200B1 (ru) 2018-11-30
LT3160952T (lt) 2021-05-10
MX2016017407A (es) 2017-04-27
CN106660982B (zh) 2020-09-08

Similar Documents

Publication Publication Date Title
CY1123906T1 (el) Αναστολεις απομεθυλασης ιστονης
CY1123475T1 (el) Αναστολεις της ειδικης για λυσινη απομεθυλασης-1
CY1124959T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1119901T1 (el) Αναστολεις απομεθυλασων ιστονων
CY1119476T1 (el) Αναστολεις της απομεθυλασης ιστονης
CY1120969T1 (el) Παραγωγα κινοξαλινης χρησιμα ως τροποποιητες fgfr κινασης
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1120361T1 (el) Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido)
CO2017002191A2 (es) Inhibidores de desmetilasa-1 específica a lisina
ECSP17006821A (es) Inhibidores de la desmetilasa-1 específica de la lisina
CY1123581T1 (el) Νεες μεθοδοι για την παραγωγη ολιγονουκλεοτιδιων
CR20150368A (es) Inhibidores de histona desmetilasa
ECSP17020172A (es) Inhibidores de histona desmetilasa
ECSP17006776A (es) Inhibidores de la desmetilasa-1 específica de la lisina
MX2016007585A (es) Inhibidores de desmetilasa-1 especifica de lisina.
CY1123216T1 (el) Αναστολεις της gls1 για την αντιμετωπιση νοσων
ECSP17023551A (es) Inhibidores de histona desmetilasa
CO2017003445A2 (es) Inhibidores de la histona desmetilasa
EA201992022A1 (ru) Терапевтическая рнк
EA201791264A1 (ru) Соединения для лечения злокачественного новообразования